A Real-World Multicenter Analysis Of First (1l) And Second Line (2l) Treatment Of Advanced Pancreatic Adenocarcinoma (Apc).

e16210Background: FOLFIRINOX (FFX), gemcitabine/nab-paclitaxel (GN) and gemcitabine (GEM) are 3 available treatments for locally advanced (LAPC) and metastatic (MPC) pancreatic cancer. Without a head-to-head trial, optimal 1L and 2L treatments and their impact on outcomes in the real world remain unclear. Methods: Pooled data from multiple cancer centers across provinces in Canada were analyzed. LAPC and MPC patients (pts) diagnosed from 2014 to 2016 who received at least 1 cycle of systemic therapy were included. Analyses were conducted to characterize 1L and 2L treatment sequences and predictive factors. We also assessed the relationship with overall survival (OS). Results: We identified 302 pts: median age 63 (IQR 56-69), 163 (54%) men, 127 (42%) ECOG ≥ 2, and 221 (73%) MPC. In the 1L setting, 48%, 38% and 14% of pts received FFX, GN and GEM, respectively. FFX was more likely used in younger pts (54% in age u003c 65 vs. 41% in age ≥ 65, p = 0.04) and those with favorable ECOG (63% in ECOG 0 vs. 13% in ECOG...